Kestra Medical Technologies Reports Strong Q3 FY26 Results with 63% Revenue Growth and Raised FY26 Guidance
Summary
Kestra Medical Technologies reported strong third-quarter fiscal 2026 financial results, featuring significant revenue growth, expanded gross margins, and an upward revision of its full-year guidance.
Key Events
-
Strong Q3 Revenue Growth
Reported revenue of $24.6 million for Q3 FY26, marking a 63% increase compared to the prior year period, driven by higher market share and WCD market expansion.
-
Expanded Gross Margin
Gross margin expanded significantly to 52.6% in Q3 FY26, up from 43.4% in the prior year period, attributed to volume leverage and cost improvement programs.
-
Raised FY26 Revenue Guidance
Increased fiscal year 2026 revenue guidance to $93 million, representing 55% growth over FY25, up from previous guidance of $91 million and initial guidance of $85 million.
-
Fortified Balance Sheet
Ended the quarter with $291 million in cash and cash equivalents, which includes net proceeds from an underwritten public offering of 6.9 million common shares that closed on December 4, 2025.
Analysis
Kestra Medical Technologies delivered a robust third quarter, showcasing significant operational improvements and strong market penetration. The substantial 63% year-over-year revenue growth, coupled with a notable expansion in gross margin to over 52%, indicates effective execution and improved profitability. The decision to raise full-year revenue guidance for FY26 further reinforces management's confidence in continued momentum. While the company still reports a net loss, these positive financial and operational metrics are critical for a growth-stage medical device company, demonstrating progress towards category leadership and a fortified balance sheet.
At the time of this filing, KMTS was trading at $21.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $13.25 to $30.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.